A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug

Investigational New Drugs

Volumn 17, Issue 1, 1999, Pages 49-56

  Judson, Ian R ^a   Beale, Philip J ^a   Trigo, José M ^a   Aherne, Wynne ^a   Crompton, Thomas ^a   Jones, David ^b   Bush, Ernie ^c   Reigner, Bruno ^d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c HOFFMANN LA ROCHE INC   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

5 fluorouracil; Capecitabine; Pharmacokinetics; Phase I trials

Indexed keywords

CAPECITABINE; DRUG METABOLITE; FLUOROURACIL; PYRIMIDINE ANTAGONIST;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; FECES ANALYSIS; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR; URINALYSIS;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; FECES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASMS; TIME FACTORS;

EID: 0032874167     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006263400888     Document Type: Article

References (14)

1. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998
2. Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H, Seeber S: Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors. J Clin Oncol 15: 389-400, 1997
3. Cao S, Lu K, Ishitsuka H, Rustum YM: Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors (Abstract). Proc Am Soc Clin Oncol 16: 226, 1997
4. TM (capecitabine), a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines (Abstract) Proc Am Soc Clin Oncol 16: 226, 1997
5. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55: 1091-1097, 1998
6. TM in colorectal cancer patients (Abstract). Proc Am Soc Clin Oncol 16: 227, 1997
7. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T: Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 16: 1795-1802, 1998
8. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16: 2977-2985, 1998
9. Cassidy J, Dirix L, Bissett D, Reigner B, Griffin T, Allman D, Osterwalder B, Van Oosterom AT: A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 4: 2755-2761, 1998
10. TM (capecitabine) in paclitaxel-refractory metastatic breast cancer (Abstract). Proc Am Soc Clin Oncol 17: 125, 1998
11. TM (capecitabine) in patients with advanced colorectal cancer (Abstract). Proc Am Soc Clin Oncol 16: 227, 1997
12. Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4: 941-948, 1998
13. Reigner B, Clive S, Cassidy J, Jodrell D, Schulz R, Goggin T, Banken L, Roos B, Utoh M, Mulligan T, Weidekamm E: Influence of the antacid Maalox® on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol (in press)
14. Heggi GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 47: 2203-2207, 1987